Compare IOSP & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOSP | ELVN |
|---|---|---|
| Founded | 1938 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.3B |
| IPO Year | 1998 | 2020 |
| Metric | IOSP | ELVN |
|---|---|---|
| Price | $76.75 | $44.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $93.00 | $43.40 |
| AVG Volume (30 Days) | 167.5K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 228.87 | 3.17 |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $1,778,000,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.10 | N/A |
| P/E Ratio | $16.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $65.51 | $14.79 |
| 52 Week High | $95.55 | $48.53 |
| Indicator | IOSP | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 60.84 |
| Support Level | $74.76 | $16.84 |
| Resistance Level | $77.08 | $48.53 |
| Average True Range (ATR) | 1.87 | 2.42 |
| MACD | 0.30 | -0.45 |
| Stochastic Oscillator | 86.00 | 56.14 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Performance Chemicals segment that derives maximum revenue, provides technology-based solutions for its customers' processes or products in personal care, home care, agrochemical, construction, mining and other industrial markets. The Fuel Specialties segment develops, manufactures, blends, markets and supplies a range of specialty chemical products used as additives in diesel, jet, marine, fuel oil and other fuels. The Oilfield Services segment develops and markets chemical solutions for drilling, completion, production, DRA and oil and gas applications.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.